Skip to content

Kiniksa Pharmaceuticals International, plc

KNSA

CIK 0001730430

← back to feed
Revenue (TTM)
$689.7M
+60.1% YoY Q1 Mar 2026
Net Income (TTM)
$67.4M
+236.6% YoY Q1 Mar 2026
EPS Diluted (TTM)
$0.84
+225.0% YoY Q1 Mar 2026
Gross Margin
88.8%
Q1 Mar 2026
Operating Margin
12.6%
Q1 Mar 2026
Net Margin
9.8%
Q1 Mar 2026
Free Cash Flow (TTM)
$71.88M
Q1 Mar 2026
Cash
$189.95M
Q1 Mar 2026
Total Debt
—
Q1 Mar 2026
Shares Outstanding
—
Q1 Mar 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings